Format

Send to

Choose Destination
Int J Mol Sci. 2014 Aug 27;15(9):15161-72. doi: 10.3390/ijms150915161.

The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors.

Author information

1
Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Campus Innenstadt, 80337 Munich, Germany. sabine.heublein@med.uni-muenchen.de.
2
Department of Pathology, Ludwig-Maximilians-University of Munich, 80337 Munich, Germany. doris.mayr@med.uni-muenchen.de.
3
Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Campus Innenstadt, 80337 Munich, Germany. miriam.lenhard@med.uni-muenchen.de.
4
Department of Pathology, Ludwig-Maximilians-University of Munich, 80337 Munich, Germany.
5
Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Campus Großhadern, 81377 Munich, Germany. miriam.lenhard@med.uni-muenchen.de.
6
Department of Anatomy III, Cell Biology, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany. mayerhofer@lrz.uni-muenchen.de.
7
Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University of Munich, Campus Innenstadt, 80337 Munich, Germany. udo.jeschke@med.uni-muenchen.de.

Abstract

Ovarian granulosa cell tumors (GCTs) are thought to arise from cells of the ovarian follicle and comprise a rare entity of ovarian masses. We recently identified the G-protein-coupled estrogen receptor (GPER/GPR30) to be present in granulosa cells, to be regulated by gonadotropins in epithelial ovarian cancer and to be differentially expressed throughout folliculogenesis. Thus, supposing a possible role of GPER in GCTs, this study aimed to analyze GPER in GCTs. GPER immunoreactivity in GCTs (n = 26; n (primary diagnosis) = 15, n (recurrence) = 11) was studied and correlated with the main clinicopathological variables. Positive GPER staining was identified in 53.8% (14/26) of GCTs and there was no significant relation of GPER with tumor size or lymph node status. Those cases presenting with strong GPER intensity at primary diagnosis showed a significant reduced overall survival (p = 0.002). Due to the fact that GPER is regulated by estrogens, as well as gonadotropins, GPER may also be affected by endocrine therapies applied to GCT patients. Moreover, with our data supposing GPER to be associated with GCT prognosis, GPER might be considered as a possible confounder when assessing the efficacy of hormone-based therapeutic approaches in GCTs.

PMID:
25167139
PMCID:
PMC4200831
DOI:
10.3390/ijms150915161
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center